

Martina Biggioggero

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/732041/martina-biggioggero-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

1,196
citations

19
h-index

34
g-index

44
ext. papers

1,452
ext. citations

5.8
avg, IF

5.1
L-index

#	Paper	IF	Citations
43	Mild cognitive impairment in psoriatic arthritis: Prevalence and associated factors. <i>Medicine (United States)</i> , 2021 , 100, e24833	1.8	0
42	Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 561-571	5.1	3
41	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021 , 40, 4039-4047	3.9	0
40	Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 661-670	3.8	1
39	Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e75	2.4	13
38	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 290	5.7	17
37	Baricitinib for COVID-19: a suitable treatment?. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 1012-1013	25.5	137
36	Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. <i>Drugs</i> , 2019 , 79, 1741-1755	12.1	31
35	Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 573-581	5.9	19
34	Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. <i>Drugs in Context</i> , 2019 , 8, 212595	5.2	28
33	The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors. <i>BioMed Research International</i> , 2019 , 2019, 6107217	3	10
32	Sex and Management of Rheumatoid Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2019 , 56, 333-345	3.5	49
31	Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 57-70	4.4	71
30	Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. <i>Modern Rheumatology</i> , 2018 , 28, 542-549	3.3	7
29	The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 1421-1429	4.4	10
28	The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. <i>BioMed Research International</i> , 2018 , 2018, 9460187	3	9
27	Sarilumab: patient-reported outcomes in rheumatoid arthritis. <i>Patient Related Outcome Measures</i> , 2018 , 9, 275-284	2.9	7

26	Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. <i>Clinical Rheumatology</i> , 2017 , 36, 1747-1755	3.9	23
25	The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. <i>Autoimmunity Reviews</i> , 2017 , 16, 1185-1195	13.6	51
24	Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 1593-1603	4.4	64
23	Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis. <i>Arthritis Care and Research</i> , 2017 , 69, 867-874	4.7	23
22	A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 1969-1978	4.4	10
21	Spotlight on mavrimumab for the treatment of rheumatoid arthritis: evidence to date. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 211-223	4.4	14
20	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 519-32	5.3	41
19	Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. <i>Arthritis Care and Research</i> , 2016 , 68, 432-9	4.7	57
18	The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. <i>Journal of International Medical Research</i> , 2016 , 44, 113-118	1.4	11
17	The challenging definition of naïve patient for biological drug use. <i>Autoimmunity Reviews</i> , 2015 , 14, 543-6	3.6	6
16	Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e5	2.4	8
15	Structural integrity versus radiographic progression in rheumatoid arthritis. <i>RMD Open</i> , 2015 , 1, e00006	5.9	7
14	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. <i>Joint Bone Spine</i> , 2014 , 81, 508-12	2.9	15
13	Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. <i>Rheumatology</i> , 2014 , 53, 1664-8	3.9	60
12	Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug?. <i>Autoimmunity Reviews</i> , 2014 , 13, 1102-8	13.6	55
11	Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 35-43	8.1	59
10	The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 730-7	5.3	8
9	Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. <i>Drug Development Research</i> , 2014 , 75 Suppl 1, S38-41	5.1	28

8	Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. <i>BioMed Research International</i> , 2014 , 2014, 831603	3	18
7	Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 44, 51-6	12.3	17
6	The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012 , 4, 213-23	3.8	9
5	Regulation of auto-antibody production by persisting auto-immune complexes on follicular dendritic cells. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, A38.1-A38	2.4	
4	Type I interferon therapy and its role in autoimmunity. <i>Autoimmunity</i> , 2010 , 43, 248-54	3	22
3	The geoeidemiology of the antiphospholipid antibody syndrome. <i>Autoimmunity Reviews</i> , 2010 , 9, A299-304	3.04	124
2	IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 900-4	2.4	28
1	Transforming growth factor beta1 in the pathogenesis of autoimmune congenital complete heart block: lesson from twins and triplets discordant for the disease. <i>Arthritis and Rheumatism</i> , 2006 , 54, 356-9		23